PMID- 38072758
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240425
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 42
IP  - 2
DP  - 2024 Jan 12
TI  - Co-administration with Men-B vaccine increases Rotavirus vaccination coverage: A 
      5-year regionwide retrospective cohort study (STORM study).
PG  - 287-294
LID - S0264-410X(23)01436-6 [pii]
LID - 10.1016/j.vaccine.2023.12.003 [doi]
AB  - INTRODUCTION: In Italy Rotavirus vaccination (RVV) is provided free of charge 
      from 2018, however, the coverage is scattered and suboptimal. The narrow time 
      frame to complete the schedule is a barrier to uptake, and co-administration with 
      other vaccines may potentially increase the coverage. Although the 
      co-administration of RV vaccine and Meningococcal Group B vaccine (MenB) is not 
      included in the product labels, we aimed at studying its impact on RVV coverage. 
      METHODS: This Surveillance study on Timing and cOverage of Rotavirus and MenB 
      vaccine co-administration (STORM study) used the Regional Vaccination Registry to 
      collect data about children born in Campania Region between January 2016 and 
      December 2020, and receiving vaccines scheduled in the first year of life. 
      RESULTS: Among the 224,110 children enrolled, 60,614 (27.0%) completed the RVV 
      schedule, with a vaccination rate that increased over time from 1.15% in 2016 to 
      56.92% in 2020. The first and last dose of RVV schedule were administered beyond 
      the recommended time in 6% of the study population, respectively. 
      Co-administration of RV vaccine with MenB vaccine increased from 0.7 % in 2016 to 
      46.85 % in 2020. Children receiving RV/MenB vaccines concomitantly had a 
      significantly higher chance of completing the RV schedule compared to those 
      receiving RVV alone during a specific appointment (94.78 % vs 72.26 %, Prevalence 
      Ratio -PR- 1.275, 95 %CI 1.245-1.295p < 0.00001). The positive driving effect of 
      RV/MenB co-administration was more evident for children receiving pentavalent (PR 
      1.288) than monovalent RVV (PR 1.115) which was confirmed when adjusted for 
      confounding variables (i.e., year of vaccination, local district, gender). 
      CONCLUSIONS: Although still far from the target, RVV coverage has increased in 
      recent years in Campania Region. Co-administration with MenB vaccine may aid in 
      increasing RVV coverage, especially for pentavalent RVV. Further safety data are 
      needed to support co-administration as a key tool to increase coverage.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Lo Vecchio, Andrea
AU  - Lo Vecchio A
AD  - Department of Translational Medical Sciences - Section of Pediatrics, University 
      of Naples Federico II, Naples, Italy. Electronic address: 
      andrea.lovecchio@unina.it.
FAU - Scarano, Sara Maria
AU  - Scarano SM
AD  - Department of Translational Medical Sciences - Section of Pediatrics, University 
      of Naples Federico II, Naples, Italy.
FAU - Palladino, Raffaele
AU  - Palladino R
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Del Bene, Margherita
AU  - Del Bene M
AD  - Department of Translational Medical Sciences - Section of Pediatrics, University 
      of Naples Federico II, Naples, Italy.
FAU - Trama, Ugo
AU  - Trama U
AD  - Drug Policy and Devices Unit, Regione Campania Health Department, Naples, Italy.
FAU - Affinito, Giuseppina
AU  - Affinito G
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Buono, Pietro
AU  - Buono P
AD  - Department of Maternal and Child Health, General Directorate for Health, Naples, 
      Italy.
FAU - Guarino, Alfredo
AU  - Guarino A
AD  - Department of Translational Medical Sciences - Section of Pediatrics, University 
      of Naples Federico II, Naples, Italy.
LA  - eng
PT  - Journal Article
DEP - 20231209
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Rotavirus Vaccines)
RN  - 0 (Meningococcal Vaccines)
SB  - IM
MH  - Male
MH  - Child
MH  - Humans
MH  - Infant
MH  - *Rotavirus
MH  - Vaccination Coverage
MH  - Retrospective Studies
MH  - *Rotavirus Vaccines
MH  - Vaccination
MH  - *Rotavirus Infections/prevention & control/epidemiology
MH  - *Meningococcal Vaccines
OTO - NOTNLM
OT  - Children
OT  - Diarrhea
OT  - Meningococcus B
OT  - Rotavirus
OT  - Vaccination
COIS- Declaration of competing interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: Andrea Lo Vecchio reports financial support was provided by University 
      of Naples Federico II. Andrea Lo Vecchio reports a relationship with University 
      of Naples Federico II that includes: funding grants. The data presented in the 
      present paper are part of the results of an Investigator-Initiated Studies 
      Program of Merck Sharp & Dohme Corp. obtained by the Corresponding author Andrea 
      Lo Vecchio. The opinions expressed in this paper are those of the authors and do 
      not represent those of Merck Sharp & Dohme Corp.
EDAT- 2023/12/11 00:42
MHDA- 2024/01/02 11:44
CRDT- 2023/12/10 21:58
PHST- 2023/06/28 00:00 [received]
PHST- 2023/11/24 00:00 [revised]
PHST- 2023/12/01 00:00 [accepted]
PHST- 2024/01/02 11:44 [medline]
PHST- 2023/12/11 00:42 [pubmed]
PHST- 2023/12/10 21:58 [entrez]
AID - S0264-410X(23)01436-6 [pii]
AID - 10.1016/j.vaccine.2023.12.003 [doi]
PST - ppublish
SO  - Vaccine. 2024 Jan 12;42(2):287-294. doi: 10.1016/j.vaccine.2023.12.003. Epub 2023 
      Dec 9.